How I treat cryptococcosis in organ transplant recipients.
Cryptococcosis is a significant opportunistic mycoses in organ transplant recipients. Topical developments in the field in the past few years have highlighted important issues and at the same time raised new questions regarding the management of this yeast. These include, for example, management of pretransplant cryptococcosis during transplant candidacy and timing of transplant in these instances; potential for donor transmission of cryptococcosis in light of recent fatal transmissions; and prevention and treatment of Cryptococcus-associated immune reconstitution syndrome. Discussed herein are challenges posed by these issues and evidence-based data to optimize the management of posttransplant cryptococcosis.
Nina
N
Singh
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D003453:Cryptococcosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000209:etiology; D019317:Evidence-Based Medicine; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000209:etiology; D016377:Organ Transplantation; D015995:Prevalence; D012307:Risk Factors; D014180:Transplantation
D000935:Antifungal Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B